Vicente Fresquet
Overview
Explore the profile of Vicente Fresquet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
592
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Larrayoz M, Garcia-Barchino M, Celay J, Etxebeste A, Jimenez M, Perez C, et al.
Nat Med
. 2023 Mar;
29(3):632-645.
PMID: 36928817
The historical lack of preclinical models reflecting the genetic heterogeneity of multiple myeloma (MM) hampers the advance of therapeutic discoveries. To circumvent this limitation, we screened mice engineered to carry...
2.
Peris I, Romero-Murillo S, Martinez-Balsalobre E, Farrington C, Arriazu E, Marcotegui N, et al.
Blood
. 2022 Dec;
141(9):1047-1059.
PMID: 36455198
Venetoclax combination therapies are becoming the standard of care in acute myeloid leukemia (AML). However, the therapeutic benefit of these drugs in older/unfit patients is limited to only a few...
3.
Fresquet V, Garcia-Barchino M, Larrayoz M, Celay J, Vicente C, Fernandez-Galilea M, et al.
Cancer Discov
. 2020 Dec;
11(5):1268-1285.
PMID: 33355179
For millions of years, endogenous retroelements have remained transcriptionally silent within mammalian genomes by epigenetic mechanisms. Modern anticancer therapies targeting the epigenetic machinery awaken retroelement expression, inducing antiviral responses that...
4.
Goicoechea I, Puig N, Cedena M, Burgos L, Cordon L, Vidriales M, et al.
Blood
. 2020 Jul;
137(1):49-60.
PMID: 32693406
Patients with multiple myeloma (MM) carrying standard- or high-risk cytogenetic abnormalities (CAs) achieve similar complete response (CR) rates, but the later have inferior progression-free survival (PFS). This questions the legitimacy...
5.
Garcia-Barchino M, Sarasquete M, Panizo C, Morscio J, Martinez A, Alcoceba M, et al.
J Pathol
. 2018 Feb;
245(1):61-73.
PMID: 29464716
The increased risk of Richter transformation (RT) in patients with chronic lymphocytic leukaemia (CLL) due to Epstein-Barr virus (EBV) reactivation during immunosuppressive therapy with fludarabine other targeted agents remains controversial....
6.
Fresquet V, Rieger M, Carolis C, Garcia-Barchino M, Martinez-Climent J
Blood
. 2014 May;
123(26):4111-9.
PMID: 24786774
Acquired resistance to targeted drugs is emerging as an obstacle to successful cancer treatment. Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. Based on...
7.
Sagardoy A, Martinez-Ferrandis J, Roa S, Bunting K, Aznar M, Elemento O, et al.
Blood
. 2013 Apr;
121(21):4311-20.
PMID: 23580662
B-cell maturation and germinal center (GC) formation are dependent on the interplay between BCL6 and other transcriptional regulators. FOXP1 is a transcription factor that regulates early B-cell development, but whether...
8.
Fresquet V, Robles E, Parker A, Martinez-Useros J, Mena M, Malumbres R, et al.
Br J Haematol
. 2012 Jul;
158(6):712-26.
PMID: 22816737
Using high-resolution genomic microarray analysis, a distinct genomic profile was defined in 114 samples from patients with splenic marginal zone lymphoma (SMZL). Deletion or uniparental disomy of chromosome 7q were...
9.
Beltran E, Fresquet V, Martinez-Useros J, Richter-Larrea J, Sagardoy A, Sesma I, et al.
Proc Natl Acad Sci U S A
. 2011 Jul;
108(30):12461-6.
PMID: 21746927
The chromosomal translocation t(11;14)(q13;q32) leading to cyclin-D1 overexpression plays an essential role in the development of mantle cell lymphoma (MCL), an aggressive tumor that remains incurable with current treatment strategies....
10.
Malumbres R, Fresquet V, Roman-Gomez J, Bobadilla M, Robles E, Altobelli G, et al.
Haematologica
. 2011 Apr;
96(7):980-6.
PMID: 21459790
Background: LMO2 is highly expressed at the most immature stages of lymphopoiesis. In T-lymphocytes, aberrant LMO2 expression beyond those stages leads to T-cell acute lymphoblastic leukemia, while in B cells...